DGAP-News

Xlife Sciences AG (XLS): Joint venture with Indivumed - Seite 2

About Xlife Sciences AG
Xlife Sciences AG is a Swiss company that focuses on the value development of promising technologies in the life science sector. The company bridges the gap between research and development and the healthcare markets. Together with industrial partners or university institutions, the company leads projects through the proof-of-concept phase following an invention disclosure or a spin-off. With this, Xlife Sciences AG enables its investors a very early and direct entry into the further development of innovative and future-oriented technologies. Further information: www.xlifesciences.ch

Information to media professionals:
Oliver R. Baumann, CEO Xlife Sciences AG, Tel. [phone], [e-mail]

---

18.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Xlife Sciences AG
	Klausstrasse 19
	8008 Zürich
	Switzerland
Phone:	0041 44 385 84 60
E-mail:	[e-mail]
Internet:	www.xlifesciences.ch
ISIN:	CH0461929603
WKN:	A2PK6Z
Listed:	Regulated Unofficial Market in Frankfurt, Munich
EQS News ID:	1176442

End of News	DGAP News Service

1176442  18.03.2021